CC-5079

A small molecule with MKP1, antiangiogenic, and antitumor activity

Huan N. Vu, Walter J. Miller, Sarah A. O'Connor, Mei He, Peter H. Schafer, Faribourz Payvandi, George W. Muller, David I. Stirling, Steven K. Libutti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: CC-5079, a small molecule inhibitor of tubulin polymerization and phosphodiesterase-4 activity, was evaluated for antiangiogenic and antitumor activities. Materials and Methods: First, CC-5079 in vitro activity on human umbilical vein endothelial cells (HUVECs), fibroblasts, and MC38 were evaluated by proliferation, migration, and invasion assays. Second, CC-5079 effect on microvessel formation was evaluated ex vivo by chick chorioallantoic membrane (CAM), rat aortic rings assays, and with directed in vivo angiogenesis assay (DIVAA). Third, CC-5079 antitumor effect was determined in treatment of C57BL/6 mice with MC38 tumors. Finally, CC-5079 modulation of MKP1 in HUVECs, human fibroblast, and MC38 were determined by RNA isolation for qRT-PCR. Results: At the 0.1 μM concentration CC-5079 significantly inhibited HUVEC, fibroblast, and MC38 proliferation and migration (all P < 0.001). At the 0.1 μM concentration, CC-5079 also inhibited HUVEC invasion (P < 0.05) but not fibroblast. In the CAM and rat aortic ring assays, CC-5079 at 0.1 μM inhibited microvessel formation (P < 0.05). By DIVAA, CC-5079 at 1 mg/kg/d continuous delivered inhibited microvessel formation (P < 0.05). Intraperitoneal CC-5079 was well tolerated and inhibited the growth of subcutaneous MC38 at 100 mg/kg/d (P < 0.01). By qRT-PCR, CC-5079 stimulated MKP1 expression in HUVEC and fibroblast. Conclusion: CC-5079 demonstrated stimulation of MKP1, antiangiogenic, and antitumor properties.

Original languageEnglish (US)
Pages (from-to)116-125
Number of pages10
JournalJournal of Surgical Research
Volume164
Issue number1
DOIs
StatePublished - Nov 2010
Externally publishedYes

Fingerprint

Human Umbilical Vein Endothelial Cells
Fibroblasts
Microvessels
Chorioallantoic Membrane
CC-5079
Tubulin Modulators
Type 4 Cyclic Nucleotide Phosphodiesterase
Polymerase Chain Reaction
Inbred C57BL Mouse
RNA
Growth
Neoplasms

Keywords

  • angiogenesis
  • Selcids
  • small molecule inhibitor

ASJC Scopus subject areas

  • Surgery

Cite this

Vu, H. N., Miller, W. J., O'Connor, S. A., He, M., Schafer, P. H., Payvandi, F., ... Libutti, S. K. (2010). CC-5079: A small molecule with MKP1, antiangiogenic, and antitumor activity. Journal of Surgical Research, 164(1), 116-125. https://doi.org/10.1016/j.jss.2009.01.031

CC-5079 : A small molecule with MKP1, antiangiogenic, and antitumor activity. / Vu, Huan N.; Miller, Walter J.; O'Connor, Sarah A.; He, Mei; Schafer, Peter H.; Payvandi, Faribourz; Muller, George W.; Stirling, David I.; Libutti, Steven K.

In: Journal of Surgical Research, Vol. 164, No. 1, 11.2010, p. 116-125.

Research output: Contribution to journalArticle

Vu, HN, Miller, WJ, O'Connor, SA, He, M, Schafer, PH, Payvandi, F, Muller, GW, Stirling, DI & Libutti, SK 2010, 'CC-5079: A small molecule with MKP1, antiangiogenic, and antitumor activity', Journal of Surgical Research, vol. 164, no. 1, pp. 116-125. https://doi.org/10.1016/j.jss.2009.01.031
Vu HN, Miller WJ, O'Connor SA, He M, Schafer PH, Payvandi F et al. CC-5079: A small molecule with MKP1, antiangiogenic, and antitumor activity. Journal of Surgical Research. 2010 Nov;164(1):116-125. https://doi.org/10.1016/j.jss.2009.01.031
Vu, Huan N. ; Miller, Walter J. ; O'Connor, Sarah A. ; He, Mei ; Schafer, Peter H. ; Payvandi, Faribourz ; Muller, George W. ; Stirling, David I. ; Libutti, Steven K. / CC-5079 : A small molecule with MKP1, antiangiogenic, and antitumor activity. In: Journal of Surgical Research. 2010 ; Vol. 164, No. 1. pp. 116-125.
@article{6cb1cdd6ca644fe8a3f646f5a7a25aa9,
title = "CC-5079: A small molecule with MKP1, antiangiogenic, and antitumor activity",
abstract = "Introduction: CC-5079, a small molecule inhibitor of tubulin polymerization and phosphodiesterase-4 activity, was evaluated for antiangiogenic and antitumor activities. Materials and Methods: First, CC-5079 in vitro activity on human umbilical vein endothelial cells (HUVECs), fibroblasts, and MC38 were evaluated by proliferation, migration, and invasion assays. Second, CC-5079 effect on microvessel formation was evaluated ex vivo by chick chorioallantoic membrane (CAM), rat aortic rings assays, and with directed in vivo angiogenesis assay (DIVAA). Third, CC-5079 antitumor effect was determined in treatment of C57BL/6 mice with MC38 tumors. Finally, CC-5079 modulation of MKP1 in HUVECs, human fibroblast, and MC38 were determined by RNA isolation for qRT-PCR. Results: At the 0.1 μM concentration CC-5079 significantly inhibited HUVEC, fibroblast, and MC38 proliferation and migration (all P < 0.001). At the 0.1 μM concentration, CC-5079 also inhibited HUVEC invasion (P < 0.05) but not fibroblast. In the CAM and rat aortic ring assays, CC-5079 at 0.1 μM inhibited microvessel formation (P < 0.05). By DIVAA, CC-5079 at 1 mg/kg/d continuous delivered inhibited microvessel formation (P < 0.05). Intraperitoneal CC-5079 was well tolerated and inhibited the growth of subcutaneous MC38 at 100 mg/kg/d (P < 0.01). By qRT-PCR, CC-5079 stimulated MKP1 expression in HUVEC and fibroblast. Conclusion: CC-5079 demonstrated stimulation of MKP1, antiangiogenic, and antitumor properties.",
keywords = "angiogenesis, Selcids, small molecule inhibitor",
author = "Vu, {Huan N.} and Miller, {Walter J.} and O'Connor, {Sarah A.} and Mei He and Schafer, {Peter H.} and Faribourz Payvandi and Muller, {George W.} and Stirling, {David I.} and Libutti, {Steven K.}",
year = "2010",
month = "11",
doi = "10.1016/j.jss.2009.01.031",
language = "English (US)",
volume = "164",
pages = "116--125",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - CC-5079

T2 - A small molecule with MKP1, antiangiogenic, and antitumor activity

AU - Vu, Huan N.

AU - Miller, Walter J.

AU - O'Connor, Sarah A.

AU - He, Mei

AU - Schafer, Peter H.

AU - Payvandi, Faribourz

AU - Muller, George W.

AU - Stirling, David I.

AU - Libutti, Steven K.

PY - 2010/11

Y1 - 2010/11

N2 - Introduction: CC-5079, a small molecule inhibitor of tubulin polymerization and phosphodiesterase-4 activity, was evaluated for antiangiogenic and antitumor activities. Materials and Methods: First, CC-5079 in vitro activity on human umbilical vein endothelial cells (HUVECs), fibroblasts, and MC38 were evaluated by proliferation, migration, and invasion assays. Second, CC-5079 effect on microvessel formation was evaluated ex vivo by chick chorioallantoic membrane (CAM), rat aortic rings assays, and with directed in vivo angiogenesis assay (DIVAA). Third, CC-5079 antitumor effect was determined in treatment of C57BL/6 mice with MC38 tumors. Finally, CC-5079 modulation of MKP1 in HUVECs, human fibroblast, and MC38 were determined by RNA isolation for qRT-PCR. Results: At the 0.1 μM concentration CC-5079 significantly inhibited HUVEC, fibroblast, and MC38 proliferation and migration (all P < 0.001). At the 0.1 μM concentration, CC-5079 also inhibited HUVEC invasion (P < 0.05) but not fibroblast. In the CAM and rat aortic ring assays, CC-5079 at 0.1 μM inhibited microvessel formation (P < 0.05). By DIVAA, CC-5079 at 1 mg/kg/d continuous delivered inhibited microvessel formation (P < 0.05). Intraperitoneal CC-5079 was well tolerated and inhibited the growth of subcutaneous MC38 at 100 mg/kg/d (P < 0.01). By qRT-PCR, CC-5079 stimulated MKP1 expression in HUVEC and fibroblast. Conclusion: CC-5079 demonstrated stimulation of MKP1, antiangiogenic, and antitumor properties.

AB - Introduction: CC-5079, a small molecule inhibitor of tubulin polymerization and phosphodiesterase-4 activity, was evaluated for antiangiogenic and antitumor activities. Materials and Methods: First, CC-5079 in vitro activity on human umbilical vein endothelial cells (HUVECs), fibroblasts, and MC38 were evaluated by proliferation, migration, and invasion assays. Second, CC-5079 effect on microvessel formation was evaluated ex vivo by chick chorioallantoic membrane (CAM), rat aortic rings assays, and with directed in vivo angiogenesis assay (DIVAA). Third, CC-5079 antitumor effect was determined in treatment of C57BL/6 mice with MC38 tumors. Finally, CC-5079 modulation of MKP1 in HUVECs, human fibroblast, and MC38 were determined by RNA isolation for qRT-PCR. Results: At the 0.1 μM concentration CC-5079 significantly inhibited HUVEC, fibroblast, and MC38 proliferation and migration (all P < 0.001). At the 0.1 μM concentration, CC-5079 also inhibited HUVEC invasion (P < 0.05) but not fibroblast. In the CAM and rat aortic ring assays, CC-5079 at 0.1 μM inhibited microvessel formation (P < 0.05). By DIVAA, CC-5079 at 1 mg/kg/d continuous delivered inhibited microvessel formation (P < 0.05). Intraperitoneal CC-5079 was well tolerated and inhibited the growth of subcutaneous MC38 at 100 mg/kg/d (P < 0.01). By qRT-PCR, CC-5079 stimulated MKP1 expression in HUVEC and fibroblast. Conclusion: CC-5079 demonstrated stimulation of MKP1, antiangiogenic, and antitumor properties.

KW - angiogenesis

KW - Selcids

KW - small molecule inhibitor

UR - http://www.scopus.com/inward/record.url?scp=77958091732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958091732&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2009.01.031

DO - 10.1016/j.jss.2009.01.031

M3 - Article

VL - 164

SP - 116

EP - 125

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -